

November 4, 2021

Quarterly Financial Summary
(For the first six months of the fiscal year ending March 31, 2022)
[Under Japanese GAAP]
(Consolidated)

Listed Company: Zeria Pharmaceutical Co., Ltd. (Stock Exchange: First Section of Tokyo Stock Exchange)
 Code Number: 4559 (URL: <https://www.zeria.co.jp/>)
 Representative: Mitsuhiro Ibe, Representative Director, President & COO
 Person in charge of reference: Tomoyuki Nishizawa, Director, Public Relations Division TEL (03) 3661-1039
 Scheduled date to submit the Quarterly Securities Report: November 8, 2021
 Scheduled date to commence dividend payments: December 1, 2021
 Preparation of supplementary documents to the quarterly financial results: Yes
 Holding of quarterly financial results presentation: Yes (for analysts, institutional investors and the press)

(Amounts under a million yen are truncated.)

1. Consolidated Financial Highlights (April 1, 2021 through September 30, 2021)

(1) Consolidated Financial Results (cumulative)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Six months ended								
September 30, 2021	28,606	12.1	2,672	67.2	3,116	138.4	2,115	52.4
September 30, 2020	25,521	–	1,598	–	1,307	–	1,388	–

Note: Comprehensive income: For the six months ended September 30, 2021: 2,194 million yen [10.9%]

For the six months ended September 30, 2020: 1,978 million yen [–%]

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Six months ended		
September 30, 2021	46.65	–
September 30, 2020	30.05	–

Note: The Company has applied the “Accounting Standard for Revenue Recognition” (ASBJ Statement No. 29, March 31, 2020) and relevant revised ASBJ regulations from the start of the first quarter of the fiscal year ending March 31, 2022, and each figure for the six months ended September 30, 2020, is the figure after retrospectively applying the accounting standard and relevant revised ASBJ regulations. Consequently, the percentage of year-on-year change of each figure for the six months ended September 30, 2020, is not shown.

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio	Net assets per share
	Million yen	Million yen	%	Yen
As of				
September 30, 2021	123,673	56,416	45.5	1,246.90
March 31, 2021	121,860	56,152	45.9	1,225.09

Reference: Equity: As of September 30, 2021: 56,235 million yen As of March 31, 2021: 55,985 million yen

Note: The Company has applied the “Accounting Standard for Revenue Recognition” (ASBJ Statement No. 29, March 31, 2020) and relevant revised ASBJ regulations from the start of the first quarter of the fiscal year ending March 31, 2022, and each figure as of March 31, 2021, is the figure after retrospectively applying the accounting standard and relevant revised ASBJ regulations.

2. Dividends

	Annual dividends				
	First quarter	Second quarter	Third quarter	Year-end	Total
Year ended March 31, 2021	Yen –	Yen 17.00	Yen –	Yen 17.00	Yen 34.00
Year ending March 31, 2022	–	17.00			
Year ending March 31, 2022 (Forecast)			–	17.00	34.00

Note: Revision of the forecast of dividends most recently announced: None

3. Consolidated Financial Forecast for the Fiscal Year Ending March 31, 2022 (April 1, 2021 through March 31, 2022)

(Percentage figures indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	60,000	13.7	5,300	52.5	5,200	62.1	3,700	17.7	81.80

Note: Revision of the financial forecast most recently announced: None

Year-on-year changes are presented in comparison with figures from the previous fiscal year after retrospective adjustments as retrospective adjustments were carried out due to changes in accounting policies.

* Notes

(1) Significant changes of subsidiaries during the six months ended September 30, 2021 (changes in specified subsidiaries resulting in changes in scope of consolidation): None

Inclusion: – (Company name: –) Exclusion: – (Company name: –)

(2) Application of special accounting for preparing the quarterly consolidated financial statements: Yes

(3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements after error corrections

1) Changes in accounting policies due to revisions to accounting standards and other regulations: Yes

2) Changes in accounting policies due to other reasons: None

3) Changes in accounting estimates: None

4) Restatement of prior period financial statements after error corrections: None

(4) Number of shares issued (common shares)

1) Number of shares issued as of the end of the period (including treasury shares):

As of September 30, 2021: 53,119,190 shares As of March 31, 2021: 53,119,190 shares

2) Number of treasury shares as of the end of the period:

As of September 30, 2021: 8,018,749 shares As of March 31, 2021: 7,420,461 shares

3) Average number of shares during the period (cumulative from the beginning of the fiscal year):

For the six months ended September 30, 2021: 45,360,392 shares

For the six months ended September 30, 2020: 46,206,490 shares

* Quarterly Financial Summary Is Exempt from Quarterly Review Conducted by Certified Public Accountants or An Audit Corporation.

* Cautionary Statement with Respect to Appropriate Use of Financial Forecast and Other Special Matters

The description about the future including the projection in this document is based on information available to the Company at present and certain presumptions which the Company considers reasonable. Consequently, any descriptions herein do not constitute assurances regarding actual results by the Company. The actual results for future terms may differ from the information in this document due to various factors.